Dyadic International
1044 North U.S. Highway One, Suite 201, Jupiter, FL, 33477-5094, United States
Overview
Dyadic International, Inc., is a global biotechnology company headquartered in Jupiter, Florida with its research and development center in the Netherlands. Dyadic uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceuticals and industrial enzyme industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 fungus which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes and proteins. Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes which these technologies help produce
- Total investments
- 2
- Lead investments
- 2
- Investments · 12mo
- 0
- Active investors
- 6
Sector focus
- Biopharma
- Biotechnology
- Manufacturing
Investment portfolio
- VLPbio
Led · Equity · Feb 2018
VLPbio develops novel veterinary vaccines using a proprietary platform based on chimeric pseudoviral particles (Ch‑VLPs) that expose specific antigens to generate immune responses. Its platform is protected by a strong portfolio of patents and is designed to be safe by not incorporating infectious material, enabling DIVA (differentiate infected from vaccinated animals) capability. The company reports promising results across indications in the poultry, bovine and swine sectors, demonstrating the platform's broad applicability. VLPbio emphasizes a solid strategic plan and an experienced team as key assets for growth. The recent financing is intended to expand and reinforce current development programs and to carry out regulatory trials needed prior to commercialization.
- BDi
Led · Equity · Jan 2018
BDi is an industrial biotech company offering end-to-end bioprocess development services, from strain improvement to industrial-scale fermentation, for pharmaceutical, veterinary and food markets. The company operates offices, laboratories and a fermentation plant in the Parque Tecnológico de Boecillo (Valladolid) in Castilla y León. BDi has sustained growth that has helped it position as a sector reference and is developing relationships with leading companies. The recently raised capital is intended to further support the company’s international expansion. Management emphasizes scientific excellence and market knowledge, and says a technically strong team has attracted strategic partners and investors. BDi is also positioned to collaborate on platform technologies such as Dyadic’s C1 expression system for lower‑cost biologics and vaccines.